These recombinant molecules can compete with ACE2 on endothelial cell surfaces for binding to SARS-CoV-2, leaving the membrane-bound ACE2 unoccupied and able to convert angiotensin II to angiotensin (1–7), thus moderating the overwhelming inflammatory response seen in COVID-19 [32]. This evidence concerns the gene ACE2 and COVID-19.